Crohn’s disease is treated with a combination of medications that calm the immune system, dietary changes that reduce gut irritation, and sometimes surgery to fix damaged sections of the intestine. There is no cure, but modern treatment can put the disease into deep remission, meaning both symptoms and underlying inflammation resolve. The American Gastroenterological Association now recommends starting with advanced therapies early rather than working up slowly from milder drugs.
Managing an Active Flare
When Crohn’s flares, the immediate goal is to bring inflammation down fast. Corticosteroids are the standard tool for this. Most prescribers start at 40 mg of prednisolone daily for one week, then taper by 5 mg each week over roughly eight weeks. This approach controls symptoms quickly but comes with real side effects: insomnia, mood swings, weight gain, and bone thinning with repeated courses. Steroids are a bridge, not a long-term solution. They suppress inflammation broadly but don’t heal the gut lining or change the course of the disease.
Budesonide is a milder steroid option that works more locally in the gut and causes fewer body-wide side effects. It’s typically used for flares affecting the end of the small intestine or the beginning of the colon. Either way, the goal is to get off steroids as quickly as possible and onto a maintenance therapy that keeps inflammation from returning.
Starting Versus Stepping Up Treatment
For decades, doctors followed a “step-up” approach: start with mild drugs and escalate only when they failed. The newer “top-down” approach flips this, starting with powerful biologic therapies right away. The AGA now suggests upfront use of advanced therapy for moderate-to-severe Crohn’s rather than beginning with corticosteroids or older immune-suppressing drugs alone.
The evidence supports this shift. In a study of patients after bowel surgery, those who started biologics within a month had significantly higher rates of complete endoscopic remission at six months (45% versus 19% with the step-up approach). They also had lower rates of visible inflammation returning in the gut (47% versus 66%). For people with risk factors like smoking, previous bowel surgery, or fistulas, early aggressive treatment appears especially important. The logic is straightforward: controlling inflammation before it causes permanent scarring or structural damage leads to better long-term outcomes.
Biologic Therapies
Biologics are lab-made proteins that target specific parts of the immune system driving Crohn’s inflammation. They’re given by injection or IV infusion and fall into three main classes, each working through a different mechanism.
The first class blocks a protein called TNF, one of the body’s strongest inflammatory alarm signals. TNF tells immune cells to ramp up their attack. By attaching to TNF and preventing it from reaching other cells, these drugs turn down that alarm, reducing inflammation and giving the intestinal lining a chance to heal. This class has the longest track record in Crohn’s treatment.
The second class, integrin blockers, takes a different approach. Instead of neutralizing an inflammatory signal, these drugs reduce the number of immune cells that can physically reach the gut. White blood cells use proteins called integrins to cross from the bloodstream into the intestinal wall. Blocking those proteins means fewer inflammatory cells arrive at the site of damage. This gut-targeted approach tends to have fewer body-wide side effects.
The third class targets two signaling proteins, IL-12 and IL-23, that activate certain white blood cells and trigger inflammatory cascades. In Crohn’s disease, these signals become overactive. Blocking them interrupts the cycle of chronic inflammation. Several drugs in this class are now recommended as first-line options alongside the other biologics.
The AGA lists seven specific advanced therapies as recommended options for moderate-to-severe Crohn’s. Your doctor’s choice among them depends on factors like where your disease is located, whether you have inflammation outside the gut (in joints or skin, for example), your insurance coverage, and whether you prefer self-injections at home or infusions at a clinic.
Small Molecule Therapies
Unlike biologics, which are large proteins that must be injected, small molecule drugs are pills taken by mouth. One class, JAK inhibitors, works inside cells rather than outside them. These drugs block enzymes called Janus kinases that relay inflammatory signals from the cell surface to the nucleus. By interrupting this relay, they dial down the production of multiple inflammatory proteins at once.
One JAK inhibitor, upadacitinib, is approved for Crohn’s disease. In a clinical trial, the highest dose group achieved endoscopic remission (visible healing of the intestinal lining) in 22% of patients, compared to 0% on placebo. That may sound modest, but endoscopic remission is a high bar, and these were patients who had already failed other treatments. JAK inhibitors are typically reserved for people who haven’t responded to biologics, though their role is expanding.
Diet as Treatment
Diet plays a more direct role in Crohn’s than in many other chronic diseases. Certain food components appear to worsen gut inflammation, and structured dietary approaches can induce remission in some patients, particularly children and adolescents.
The Crohn’s Disease Exclusion Diet (CDED) is a three-phase whole food diet used alongside partial enteral nutrition (liquid formula supplements). In the first six weeks, the diet is highly restrictive: gluten-free, dairy-free, with rice as the only allowed grain. Soluble fiber is emphasized while insoluble and fermentable fibers are reduced. Liquid formula provides about 50% of daily calories, typically two to three bottles per day.
In the second six-week phase, the diet loosens. Gluten, oatmeal, quinoa, legumes, and more fruits and vegetables are reintroduced. Formula drops to about 25% of calories. Phase three is a long-term maintenance plan that allows most foods, with yogurt added and two unrestricted “free days” per week.
Beyond structured protocols, most people with Crohn’s benefit from identifying personal trigger foods. Common culprits include high-fat or fried foods, raw vegetables, seeds, nuts, popcorn, and alcohol. Keeping a food diary during stable periods helps you distinguish true triggers from coincidences.
When Surgery Becomes Necessary
Up to 75% of people with Crohn’s will need at least one surgery in their lifetime. Surgery doesn’t cure the disease, but it can remove damaged tissue and resolve complications that medications can’t fix.
Intestinal strictures, sections of the bowel that have narrowed from chronic scarring, are the most common reason for surgery. When a stricture is short, a procedure called strictureplasty can widen the narrowed area without removing any intestine. This preserves bowel length, which matters because Crohn’s can recur and further surgeries may be needed down the line. For longer or more severely damaged segments, a bowel resection removes the affected section and reconnects the healthy ends.
Other surgical situations include fistulas (abnormal tunnels between the intestine and other organs or the skin surface), abscesses that need draining, intestinal perforations, and severe bleeding that doesn’t respond to other treatment. In rare cases involving extensive colon damage or precancerous changes, removal of part or all of the colon and rectum may be necessary. This sometimes requires an ostomy, where a surgically created opening in the abdomen allows waste to exit into an external pouch.
After surgery, the question of how aggressively to prevent recurrence matters enormously. Starting biologic therapy within the first month after bowel resection leads to better outcomes than waiting, especially if you have known risk factors for recurrence.
Tracking Your Inflammation
Symptoms alone are unreliable guides to what’s happening inside the gut. Many people with Crohn’s feel fine while silent inflammation slowly damages their intestinal wall. This is why objective monitoring is a core part of treatment.
Fecal calprotectin is a stool test that measures a protein released by inflamed intestinal tissue. It’s noninvasive and gives a useful snapshot between colonoscopies. Levels above 250 micrograms per kilogram generally indicate active disease. Levels below 56 predict sustained remission with high specificity, meaning if your number is that low, the chance of a flare in the near term is very small. The goal of treatment is to push calprotectin levels down and keep them there, not just to make symptoms disappear.
Colonoscopy remains the gold standard for assessing mucosal healing directly. Most gastroenterologists recommend a scope six to twelve months after starting or changing therapy, then at regular intervals. MRI of the small bowel is used to monitor disease in areas the colonoscope can’t reach. Together, these tools let your care team adjust treatment before damage accumulates, rather than reacting after symptoms return.